Clinical Trial: NCT03336333
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 3| Lead Sponsor: | BeiGene |
| Information Provided By: | BeOne Medicines |
| Last Update Posted: | 2026-03-09 |
Study Overview
Brief Summary
To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression free survival assess by Independent Central Review.
Official Title
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Intervention / Treatment
- Drug: Zanubrutinib
- Drug: Bendamustine
- Drug: Rituximab
- Drug: Venetoclax
Other Study ID Numbers
- BGB-3111-304
- 2017-001551-31
- CTR20190416
- 2017
Start Date (Actual)
2017-10-31
Primary Completion Date (Actual)
2021-05-07
Study Completion Date (Estimated)
2027-10-31
Enrollment (Actual)
590
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | BeiGene |
| Information Provided By: | BeOne Medicines |
| Last Update Posted: | 2026-03-09 |
Study Overview
Brief Summary
To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression free survival assess by Independent Central Review.
Official Title
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Intervention / Treatment
- Drug: Zanubrutinib
- Drug: Bendamustine
- Drug: Rituximab
- Drug: Venetoclax
Other Study ID Numbers
- BGB-3111-304
- 2017-001551-31
- CTR20190416
- 2017
Start Date (Actual)
2017-10-31
Primary Completion Date (Actual)
2021-05-07
Study Completion Date (Estimated)
2027-10-31
Enrollment (Actual)
590
Study Type
Interventional
Phase
Phase 3